Description
Anti-CTLA-4 Antibody, Highly Galactosylated (BioBet-GA-027ZP) is a human IgG1 antibody against CTLA-4 which contains with a high level of galactosylation.
Antibody Indication
Advanced Renal Cell Carcinoma
Cutaneous Melanoma
Metastatic Melanoma
Unresectable Melanoma
Metastatic MSI-H/dMMR colorectal cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CTLA-4 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
cytotoxic T-lymphocyte associated protein 4
Background
This gene is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases.
Alternative Names
CD; GSE; GRD4; ALPS5; CD152; CTLA-4; IDDM12; CELIAC3
Cellular Localization
Plasma membrane
Involvement in Disease
Its related pathways are TCR Signaling (Qiagen) and T cell receptor signaling pathway.
Related Pathways
Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28.
Field of research
1.N-glycosylation is important for dimerization. 2.Phosphorylation at Tyr-201 prevents binding to the AP-2 adapter complex, blocks endocytosis, and leads to retention of CTLA4 on the cell surface.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
BioBet-GA-027ZP
Description
Ipilimumab is a monoclonal antibody against cytotoxic T lymphocyte antigen 4 (CTLA-4). Specifically, it is a fully humanized IgG1 antibody produced in mammalian cell culture. The antibody activates the immune system by inhibiting this major checkpoint. It is currently undergoing clinical trials for the treatment of non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), bladder cancer, and metastatic hormone-refractory prostate cancer.
Antibody Indication
Advanced Renal Cell Carcinoma
Cutaneous Melanoma
Metastatic Melanoma
Unresectable Melanoma
Metastatic MSI-H/dMMR colorectal cancer
